Effects of Transarterial Chemoembolization on the Immunological Function of Patients with Hepatocellular Carcinoma

Overview

Journal Oncol Lett

Specialty Oncology

Date 2021 Jun 4

PMID 34084221

Citations 18

Authors

Jingjing Guo

Saixia Wang

Yujing Han

Zhongyuan Jia

Runchao Wang

Affiliations

Soon will be listed here.

Abstract

The present study aimed to investigate the effects of transarterial chemoembolization (TACE) on the immune function of patients with hepatocellular carcinoma (HCC). A total of 114 patients with HCC were selected and their peripheral blood was collected before and 1 month after TACE treatment. Flow cytometry and reverse transcription-quantitative PCR were performed to analyze the changes in immune function in patients before and after treatment. Kaplan-Meier curves were plotted for survival analysis. The programmed cell death ligand 1 (PD-L1) and programmed cell death protein 1 (PD1) expression before TACE treatment were significantly higher in patients with poor TACE response compared with those patients with well response. Higher PD-L1 mRNA expression in the peripheral blood mononuclear cells after TACE predicted a superior prognosis. After TACE treatment, the proportion of CD4/CD8 cells were decreased while the expression levels of programmed cell death protein 1 (PD1) were significantly increased. To conclude, TACE could reduce the proportion of CD4/CD8 cells and improve the mRNA expression levels of PD1 in patients with HCC. The expression levels of PD1 and PD-L1 were closely related to the therapeutic effect of TACE and the prognosis of patients with HCC. TACE combined with immunotherapy may have potential clinical value for patients with HCC.

Citing Articles

Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable....

Kodama Y, Ueshima K, Moriguchi M, Inaba Y, Yamashita T, Iwamoto H BMC Cancer. 2025; 25(1):434.

PMID: 40069616 PMC: 11895279. DOI: 10.1186/s12885-025-13648-5.

Transarterial chemoembolization combined with lenvatinib and sintilimab lenvatinib alone in intermediate-advanced hepatocellular carcinoma.

Wu F, Zhou H, Yang W, Zhu D, Wu B, Shi H World J Gastrointest Oncol. 2025; 17(1):96267.

PMID: 39817120 PMC: 11664616. DOI: 10.4251/wjgo.v17.i1.96267.

Immune effect and prognosis of transcatheter arterial chemoembolization and tyrosine kinase inhibitors therapy in patients with hepatocellular carcinoma.

Guo Y, Li R, Xia W, Yang X, Zhu W, Li F World J Gastrointest Oncol. 2024; 16(7):3256-3269.

PMID: 39072154 PMC: 11271774. DOI: 10.4251/wjgo.v16.i7.3256.

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate-stage Hepatocellular Carcinoma: A Multicenter Retrospective Study.

Zheng Y, Xiang Y, Shi H, Lin Z, Cheng S, Zhu J J Hepatocell Carcinoma. 2024; 11:1079-1093.

PMID: 38882440 PMC: 11180435. DOI: 10.2147/JHC.S461630.

The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications.

Chen K, Shuen T, Chow P Br J Cancer. 2024; 131(3):420-429.

PMID: 38760445 PMC: 11300599. DOI: 10.1038/s41416-024-02684-w.

References

Wallace M, Preen D, Jeffrey G, Adams L . The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015; 9(6):765-79. DOI: 10.1586/17474124.2015.1028363. View

Zhu Z, Huang J, Liao M, Zeng Y . Treatment strategy for hepatocellular carcinoma in China: radiofrequency ablation versus liver resection. Jpn J Clin Oncol. 2016; 46(12):1075-1080. DOI: 10.1093/jjco/hyw134. View

Quezada S, Peggs K, Simpson T, Allison J . Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev. 2011; 241(1):104-18. PMC: 3727276. DOI: 10.1111/j.1600-065X.2011.01007.x. View

Naruse T, Yanamoto S, Okuyama K, Ohmori K, Tsuchihashi H, Furukawa K . Immunohistochemical Study of PD-1/PD-L1 Axis Expression in Oral Tongue Squamous Cell Carcinomas: Effect of Neoadjuvant Chemotherapy on Local Recurrence. Pathol Oncol Res. 2019; 26(2):735-742. DOI: 10.1007/s12253-019-00606-3. View

Shimura S, Odagiri S, Furuya H, Okada K, Ozawa K, Nagase H . Echocardiography-guided aortic cannulation by the Seldinger technique for type A dissection with cerebral malperfusion. J Thorac Cardiovasc Surg. 2019; 159(3):784-793. DOI: 10.1016/j.jtcvs.2019.02.097. View

Park J, Chen M, Colombo M, Roberts L, Schwartz M, Chen P . Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015; 35(9):2155-66. PMC: 4691343. DOI: 10.1111/liv.12818. View

Hanna G, Woo S, Li Y, Barletta J, Hammerman P, Lorch J . Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma. Int J Oral Maxillofac Surg. 2017; 47(5):568-577. DOI: 10.1016/j.ijom.2017.09.006. View

Kawahara T, Ishiguro Y, Ohtake S, Kato I, Ito Y, Ito H . PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer. BMC Urol. 2018; 18(1):97. PMC: 6219206. DOI: 10.1186/s12894-018-0414-8. View

Veloza L, Teixido C, Castrejon N, Climent F, Carrio A, Marginet M . Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome. Histopathology. 2019; 75(6):799-812. DOI: 10.1111/his.13857. View

10.

Loffler M, Nussbaum B, Jager G, Jurmeister P, Budczies J, Pereira P . A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer. Front Immunol. 2019; 10:2526. PMC: 6877671. DOI: 10.3389/fimmu.2019.02526. View

11.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

12.

Liu J, Liu Y, Meng L, Liu K, Ji B . Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Oncol Rep. 2017; 38(2):899-907. PMC: 5561980. DOI: 10.3892/or.2017.5722. View

13.

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8):1321-1328. PMC: 7389252. DOI: 10.1093/annonc/mdz167. View

14.

Wang Z, Zhang C, Liu X, Wang Z, Sun L, Li G . Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. Oncoimmunology. 2016; 5(11):e1196310. PMC: 5139638. DOI: 10.1080/2162402X.2016.1196310. View

15.

Darvin P, Toor S, Sasidharan Nair V, Elkord E . Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018; 50(12):1-11. PMC: 6292890. DOI: 10.1038/s12276-018-0191-1. View

16.

Lei C, Ren D, Fu M, Sun C, Ren H, Pan Q . Curative effect of endostar combined with oxaliplatin in the treatment of primary hepatic carcinoma and its influence on immune cells. Oncol Lett. 2019; 17(4):3665-3670. PMC: 6403513. DOI: 10.3892/ol.2019.10022. View

17.

Walcher L, Kistenmacher A, Suo H, Kitte R, Dluczek S, Strauss A . Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. Front Immunol. 2020; 11:1280. PMC: 7426526. DOI: 10.3389/fimmu.2020.01280. View

18.

Lee J, Lee J, Lim Y, Yeon J, Song T, Yu S . Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunol Immunother. 2018; 68(1):23-32. PMC: 6326973. DOI: 10.1007/s00262-018-2247-4. View

19.

Ge P, Wang W, Li L, Zhang G, Gao Z, Tang Z . Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of colorectal cancer. Biomed Pharmacother. 2019; 118:109228. DOI: 10.1016/j.biopha.2019.109228. View

20.

Gonzalez H, Hagerling C, Werb Z . Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018; 32(19-20):1267-1284. PMC: 6169832. DOI: 10.1101/gad.314617.118. View